Literature DB >> 14742671

Multiple pharmacophores for the investigation of human UDP-glucuronosyltransferase isoform substrate selectivity.

Michael J Sorich1, John O Miners, Ross A McKinnon, Paul A Smith.   

Abstract

The UDP-glucuronosyltransferase (UGT) enzyme 'superfamily' contributes to the metabolism of a myriad of drugs, nondrug xenobiotic agents, and endogenous compounds. Although the individual UGT isoforms exhibit distinct but overlapping substrate selectivities, structural features of substrates that confer selectivity remain largely unknown. Using methods developed for pharmacophore fingerprinting combined with optimization and pattern recognition techniques, subsets of pharmacophores associated with the substrates and nonsubstrates of 12 human UGT isoforms were selected to generate predictive models of substrate selectivity and to elucidate the chemical and structural features associated with substrates and nonsubstrates. For all 12 UGT isoforms, the pharmacophore model generated showed predictive ability, as determined by a test set comprising 30% of the available data for each isoform. Models for UGT1A6, -1A7, -1A9, and -2B4 displayed the best predictive ability (>75% of test set predicted correctly) and were further analyzed to interpret the pharmacophores selected as important. The individual pharmacophores differed among isoforms but generally represented relatively simple structural and chemical features. For example, an aromatic ring attached to the nucleophilic group was found to increase the likelihood of glucuronidation by UGT1A6, UGT1A7 and UGT1A9. A large hydrophobic region close to the nucleophile and a hydrogen bond acceptor 10 A from the nucleophile were found to be common to most UGT2B4 substrates. The pharmacophores further suggest that the environment immediately adjacent to the nucleophilic site of conjugation is an important determinant of metabolism by a particular UGT.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14742671     DOI: 10.1124/mol.65.2.301

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  7 in total

1.  Genome-wide association of serum bilirubin levels in Korean population.

Authors:  Tae-Wook Kang; Hee-Jin Kim; Hyoungseok Ju; Jeong-Hwan Kim; Yeo-Jin Jeon; Han-Chul Lee; Ka-Kyung Kim; Jong-Won Kim; Siwoo Lee; Jong Yeol Kim; Seon-Young Kim; Yong Sung Kim
Journal:  Hum Mol Genet       Date:  2010-07-16       Impact factor: 6.150

2.  Accurate prediction of glucuronidation of structurally diverse phenolics by human UGT1A9 using combined experimental and in silico approaches.

Authors:  Baojian Wu; Xiaoqiang Wang; Shuxing Zhang; Ming Hu
Journal:  Pharm Res       Date:  2012-06       Impact factor: 4.200

Review 3.  Predicting the oxidative metabolism of statins: an application of the MetaSite algorithm.

Authors:  Giulia Caron; Giuseppe Ermondi; Bernard Testa
Journal:  Pharm Res       Date:  2007-03       Impact factor: 4.200

4.  Uridine diphosphate glucuronosyltransferase isoform-dependent regiospecificity of glucuronidation of flavonoids.

Authors:  Rashim Singh; Baojian Wu; Lan Tang; Ming Hu
Journal:  J Agric Food Chem       Date:  2011-06-06       Impact factor: 5.279

Review 5.  Understanding substrate selectivity of human UDP-glucuronosyltransferases through QSAR modeling and analysis of homologous enzymes.

Authors:  Dong Dong; Roland Ako; Ming Hu; Baojian Wu
Journal:  Xenobiotica       Date:  2012-03-02       Impact factor: 1.908

Review 6.  In silico pharmacology for drug discovery: applications to targets and beyond.

Authors:  S Ekins; J Mestres; B Testa
Journal:  Br J Pharmacol       Date:  2007-06-04       Impact factor: 8.739

7.  Potential activity of fevicordin-A from Phaleria macrocarpa (Scheff) Boerl. seeds as estrogen receptor antagonist based on cytotoxicity and molecular modelling studies.

Authors:  Muchtaridi Muchtaridi; Muhammad Yusuf; Ajeng Diantini; Sy Bing Choi; Belal O Al-Najjar; Jerry V Manurung; Anas Subarnas; Tri H Achmad; Savitri R Wardhani; Habibah A Wahab
Journal:  Int J Mol Sci       Date:  2014-04-25       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.